Platelet glycoprotein IIb/IIIa antagonists for acute ischemic stroke
| Autor: | Julien Bogousslavsky, Jacques R. Leclerc |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Vascular disease business.industry medicine.medical_treatment Ischemia Antagonist Platelet Glycoprotein GPIIb-IIIa Complex medicine.disease Platelet membrane glycoprotein Gastroenterology Brain Ischemia Stroke medicine.anatomical_structure Internal medicine Anesthesia Acute Disease medicine Humans Thrombolytic Agent Neurology (clinical) business Platelet Aggregation Inhibitors Artery |
| Zdroj: | Annual Advances in Stroke Management |
| ISSN: | 1526-632X 0028-3878 |
| DOI: | 10.1212/wnl.57.suppl_2.s53 |
| Popis: | Although thrombolytic therapy is approved in several countries for treatment of ischemic stroke, only a small number of patients are eligible for treatment. Additional agents that could restore or improve cerebral flow are needed. Reperfusion agents such as platelet glycoprotein (GP) IIb/IIIa antagonists, alone or in combination with reduced doses of thrombolytic agents, have the potential for improving safety and efficacy compared with standard recombinant tissue plasminogen activator (rt-PA). In addition, GP IIb/IIIa antagonists may permit expansion beyond the current 3-hour window after symptom onset that is used for rt-PA. On the basis of experience in acute coronary syndromes, parenteral GP IIb/IIIa antagonists may have potential applications in the treatment of acute ischemic stroke and as adjunctive therapy to carotid angioplasty. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|